Ovid Therapeutics Net Income
| OVID Stock | USD 1.42 0.08 5.33% |
As of the 16th of February 2026, Ovid Therapeutics holds the Coefficient Of Variation of 2385.33, semi deviation of 4.99, and Risk Adjusted Performance of 0.0425. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Ovid Therapeutics, as well as the relationship between them. Please check Ovid Therapeutics information ratio, as well as the relationship between the value at risk and expected short fall to decide if Ovid Therapeutics is priced some-what accurately, providing market reflects its current price of 1.42 per share. Please also confirm Ovid Therapeutics total risk alpha, which is currently at (0.21) to check out the company can sustain itself at a future point.
Ovid Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 13.5609 | Revenue | Earnings Share (0.50) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -23.8 M | -25 M | |
| Net Loss | -62.3 M | -59.2 M | |
| Net Loss | -23.8 M | -25 M | |
| Net Loss | (0.34) | (0.35) | |
| Net Income Per E B T | 0.89 | 0.79 |
Ovid | Net Income | Build AI portfolio with Ovid Stock |
Analyzing Ovid Therapeutics's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Ovid Therapeutics's current valuation and future prospects.
Latest Ovid Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Ovid Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Ovid Therapeutics financial statement analysis. It represents the amount of money remaining after all of Ovid Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Ovid Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ovid Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (26.43 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Ovid Net Income Regression Statistics
| Arithmetic Mean | (20,629,177) | |
| Geometric Mean | 10,911,195 | |
| Coefficient Of Variation | (219.25) | |
| Mean Deviation | 29,628,685 | |
| Median | (23,789,700) | |
| Standard Deviation | 45,229,607 | |
| Sample Variance | 2045.7T | |
| Range | 203.6M | |
| R-Value | (0.19) | |
| Mean Square Error | 2106.1T | |
| R-Squared | 0.03 | |
| Significance | 0.47 | |
| Slope | (1,671,508) | |
| Total Sum of Squares | 32731.5T |
Ovid Net Income History
Other Fundumenentals of Ovid Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Ovid Therapeutics Net Income component correlations
Ovid Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Ovid Therapeutics is extremely important. It helps to project a fair market value of Ovid Stock properly, considering its historical fundamentals such as Net Income. Since Ovid Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Ovid Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Ovid Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Ovid diversify its offerings? Factors like these will boost the valuation of Ovid Therapeutics. Anticipated expansion of Ovid directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Ovid Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.50) | Revenue Per Share | Quarterly Revenue Growth (0.24) | Return On Assets | Return On Equity |
Ovid Therapeutics's market price often diverges from its book value, the accounting figure shown on Ovid's balance sheet. Smart investors calculate Ovid Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Ovid Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Ovid Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Ovid Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Ovid Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Ovid Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Ovid Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Ovid Therapeutics.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in Ovid Therapeutics on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding Ovid Therapeutics or generate 0.0% return on investment in Ovid Therapeutics over 90 days. Ovid Therapeutics is related to or competes with Context Therapeutics, MacroGenics, Clene, Oramed Pharmaceuticals, Shattuck Labs, ImageneBio, and Connect Biopharma. Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurolo... More
Ovid Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Ovid Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Ovid Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.49 | |||
| Information Ratio | 0.0304 | |||
| Maximum Drawdown | 36.13 | |||
| Value At Risk | (9.09) | |||
| Potential Upside | 9.7 |
Ovid Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ovid Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Ovid Therapeutics' standard deviation. In reality, there are many statistical measures that can use Ovid Therapeutics historical prices to predict the future Ovid Therapeutics' volatility.| Risk Adjusted Performance | 0.0425 | |||
| Jensen Alpha | 0.0932 | |||
| Total Risk Alpha | (0.21) | |||
| Sortino Ratio | 0.0337 | |||
| Treynor Ratio | 0.0968 |
Ovid Therapeutics February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0425 | |||
| Market Risk Adjusted Performance | 0.1068 | |||
| Mean Deviation | 4.41 | |||
| Semi Deviation | 4.99 | |||
| Downside Deviation | 5.49 | |||
| Coefficient Of Variation | 2385.33 | |||
| Standard Deviation | 6.08 | |||
| Variance | 36.99 | |||
| Information Ratio | 0.0304 | |||
| Jensen Alpha | 0.0932 | |||
| Total Risk Alpha | (0.21) | |||
| Sortino Ratio | 0.0337 | |||
| Treynor Ratio | 0.0968 | |||
| Maximum Drawdown | 36.13 | |||
| Value At Risk | (9.09) | |||
| Potential Upside | 9.7 | |||
| Downside Variance | 30.09 | |||
| Semi Variance | 24.95 | |||
| Expected Short fall | (5.45) | |||
| Skewness | 0.6502 | |||
| Kurtosis | 1.96 |
Ovid Therapeutics Backtested Returns
Ovid Therapeutics appears to be dangerous, given 3 months investment horizon. Ovid Therapeutics maintains Sharpe Ratio (i.e., Efficiency) of 0.049, which implies the firm had a 0.049 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Ovid Therapeutics, which you can use to evaluate the volatility of the company. Please evaluate Ovid Therapeutics' Semi Deviation of 4.99, coefficient of variation of 2385.33, and Risk Adjusted Performance of 0.0425 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Ovid Therapeutics holds a performance score of 3. The company holds a Beta of 2.53, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Ovid Therapeutics will likely underperform. Please check Ovid Therapeutics' total risk alpha, expected short fall, market facilitation index, as well as the relationship between the value at risk and daily balance of power , to make a quick decision on whether Ovid Therapeutics' historical price patterns will revert.
Auto-correlation | -0.33 |
Poor reverse predictability
Ovid Therapeutics has poor reverse predictability. Overlapping area represents the amount of predictability between Ovid Therapeutics time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Ovid Therapeutics price movement. The serial correlation of -0.33 indicates that nearly 33.0% of current Ovid Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.33 | |
| Spearman Rank Test | -0.47 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Ovid Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Ovid Therapeutics reported net income of (26.43 Million). This is 107.75% lower than that of the Biotechnology sector and 137.74% lower than that of the Health Care industry. The net income for all United States stocks is 104.63% higher than that of the company.
Ovid Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ovid Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ovid Therapeutics could also be used in its relative valuation, which is a method of valuing Ovid Therapeutics by comparing valuation metrics of similar companies.Ovid Therapeutics is currently under evaluation in net income category among its peers.
Ovid Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Ovid Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Ovid Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Ovid Therapeutics' value.| Shares | Wells Fargo & Co | 2025-06-30 | 763.1 K | Gsa Capital Partners Llp | 2025-06-30 | 742.2 K | Tls Advisors Llc | 2025-06-30 | 681 K | Affinity Asset Advisors, Llc | 2025-06-30 | 667.5 K | Geode Capital Management, Llc | 2025-06-30 | 643.3 K | Rosalind Advisors, Inc. | 2025-06-30 | 500 K | Rubric Capital Management Lp | 2025-06-30 | 478.5 K | Assenagon Asset Management Sa | 2025-06-30 | 435.6 K | Goldman Sachs Group Inc | 2025-06-30 | 283.8 K | Takeda Pharmaceutical Co Ltd | 2025-06-30 | 7.5 M | Bvf Inc | 2025-06-30 | 3.9 M |
Ovid Fundamentals
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (94.87) % | ||||
| Current Valuation | 89.64 M | ||||
| Shares Outstanding | 71.21 M | ||||
| Shares Owned By Insiders | 9.81 % | ||||
| Shares Owned By Institutions | 38.90 % | ||||
| Number Of Shares Shorted | 4.84 M | ||||
| Price To Earning | 1.11 X | ||||
| Price To Book | 2.27 X | ||||
| Price To Sales | 15.30 X | ||||
| Revenue | 566 K | ||||
| Gross Profit | 6.61 M | ||||
| EBITDA | (57.77 M) | ||||
| Net Income | (26.43 M) | ||||
| Cash And Equivalents | 152.37 M | ||||
| Cash Per Share | 2.16 X | ||||
| Total Debt | 14.76 M | ||||
| Debt To Equity | 0.10 % | ||||
| Current Ratio | 16.94 X | ||||
| Book Value Per Share | 0.63 X | ||||
| Cash Flow From Operations | (55.96 M) | ||||
| Short Ratio | 3.12 X | ||||
| Earnings Per Share | (0.50) X | ||||
| Target Price | 4.05 | ||||
| Number Of Employees | 23 | ||||
| Beta | 0.26 | ||||
| Market Capitalization | 101.12 M | ||||
| Total Asset | 92.17 M | ||||
| Retained Earnings | (304.3 M) | ||||
| Working Capital | 45.42 M | ||||
| Current Asset | 74.21 M | ||||
| Current Liabilities | 5.13 M | ||||
| Net Asset | 92.17 M |
About Ovid Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ovid Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ovid Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ovid Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ovid Therapeutics is a strong investment it is important to analyze Ovid Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ovid Therapeutics' future performance. For an informed investment choice regarding Ovid Stock, refer to the following important reports:Check out For information on how to trade Ovid Stock refer to our How to Trade Ovid Stock guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Will Biotechnology sector continue expanding? Could Ovid diversify its offerings? Factors like these will boost the valuation of Ovid Therapeutics. Anticipated expansion of Ovid directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Ovid Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.50) | Revenue Per Share | Quarterly Revenue Growth (0.24) | Return On Assets | Return On Equity |
Ovid Therapeutics's market price often diverges from its book value, the accounting figure shown on Ovid's balance sheet. Smart investors calculate Ovid Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Ovid Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Ovid Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Ovid Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Ovid Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.